Logo image
Long-term follow-up after proton beam therapy for pediatric tumors: a Japanese national survey
期刊文章   同儕審查

Long-term follow-up after proton beam therapy for pediatric tumors: a Japanese national survey

Masashi Mizumoto, Shigeyuki Murayama, Tetsuo Akimoto, Yusuke Demizu, Takashi Fukushima, Yuji Ishida, Yoshiko Oshiro, Haruko Numajiri, Hiroshi Fuji, Toshiyuki Okumura, …
Cancer science, 卷.108(3), 頁碼.444-447
03/2017
PMID: 28004469
Web of Science ID: WOS:000398037300020

摘要

Adolescent Adult Child Child, Preschool Female Follow-Up Studies Humans Infant Japan - epidemiology Male Neoplasms - radiotherapy Neoplasms, Radiation-Induced - epidemiology Proton Therapy - adverse effects Radiotherapy Dosage Retrospective Studies Surveys and Questionnaires Young Adult
Proton beam therapy (PBT) is a potential new alternative to treatment with photon radiotherapy that may reduce the risk of late toxicity and secondary cancer, especially for pediatric tumors. The goal of this study was to evaluate the long-term benefits of PBT in cancer survivors. A retrospective observational study of pediatric patients who received PBT was performed at four institutions in Japan. Of 343 patients, 62 were followed up for 5 or more years. These patients included 40 males and 22 females, and had a median age of 10 years (range: 0-19 years) at the time of treatment. The irradiation dose ranged from 10.8 to 81.2 GyE (median: 50.4 GyE). The median follow-up period was 8.1 years (5.0-31.2 years). The 5-, 10- and 20-year rates for grade 2 or higher late toxicities were 18%, 35% and 45%, respectively, and those for grade 3 or higher late toxicities were 6%, 17% and 17% respectively. Univariate analysis showed that the irradiated site (head and neck, brain) was significantly associated with late toxicities. No malignant secondary tumors occurred within the irradiated field. The 10- and 20-year cumulative rates for all secondary tumors, malignant secondary tumors, and malignant nonhematologic secondary tumors were 8% and 16%, 5% and 13%, and 3% and 11%, respectively. Our data indicate that PBT has the potential to reduce the risk of late mortality and secondary malignancy. Longer follow-up is needed to confirm the benefits of PBT for pediatric tumors.

檔案與連結 (1)

url
https://doi.org/10.1111/cas.13140檢視
已出版(紀錄版本) 開放

相關連結

詳細資料

Logo image